Summary
One simple step to overall K+ control
Efficacy for all
Works from the 1st dose
Lowers serum K+ from the first dose, regardless of HK severity2
Sustained K+ Control
Proven to sustain K+ within normokalemia range over 52 weeks3
Proven efficacy in different patient profiles
Proven efficacy with concomitant RAASi use backed by 4 placebo-controlled trials across comorbidities,4–7 and in the real-world setting for haemodialysis patients8,9
Patient friendly
One sachet daily from the start
80–90% of patients need a 8.4 g sachet per day1,9
Odourless, taste-free
Proven in a palatability study to be a positive experience in terms of odour and taste9
Juice or soft food mixing options
Extra versatility to suit individual tastes1
Designed for tolerability
Na+ free exchange
Suitable for Na+ sensitive patients with no Na+ associated risk1
Minimal GI effects
Optimised physical characteristics to minimise undesirable GI effect1,10
References & footnotes
Abbreviations
GI, gastrointestinal; HK, hyperkalemia; K+, potassium; Na+, sodium; RAASi, renin-angiotensin-aldosterone-system inhibitor; SAEs, serious adverse events.
References
- Veltassa® European SmPC, 2024.
- Di Palo KE, et al. JAMA Netw Open. 2022;5(1):e2145236.
- Bakris GL, et al. JAMA. 2015;314(2):151–61.
- Butler J, et al. Eur J heart Fail. 2022;24(1):230–238.
- Weir MR, et al. N Engl J Med. 2015;372(3):211–21.
- Agarwal R, et al. Lancet. 2019;394:1540–50.
- Pitt B, et al. Eur Heart J. 2011;32:820–8.
- Kovesdy CP, et al. Kidney Int Rep 2019;4(2):301–9.
- Brenner M, et al. Poster P4-075, American Society of Health System Pharmacists Annual Meeting. Las Vegas, NV.
- Li L, et al. J Card Pharmacol Ther. 2016;21(5):456–65.
HQ-PAT-2400061 | Date of preparation: February 2025